Evaluating the effect of postmastectomy radiotherapy and extent of axillary surgery in cancer patients with 1-2 positive lymph nodes.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
776 patients met inclusion criteria, with 39,319 (55%) receiving postmastectomy radiation therapy.
I · Intervention 중재 / 시술
axillary lymph node dissection
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Data from the National Cancer Database support omission of further axillary surgery in patients with early-stage breast cancer with 1 to 2 positive lymph nodes undergoing postmastectomy radiation therapy and confirm the benefit of postmastectomy radiation therapy shown in most prospective studies.
OpenAlex 토픽 ·
Breast Cancer Treatment Studies
Lymphatic System and Diseases
Nonmelanoma Skin Cancer Studies
[BACKGROUND] Radiation therapy prevents locoregional recurrence and improves outcomes in patients with positive lymph nodes undergoing mastectomy.
- p-value P < .001
APA
Walter R F Donica, Jeremy Gaskins, et al. (2026). Evaluating the effect of postmastectomy radiotherapy and extent of axillary surgery in cancer patients with 1-2 positive lymph nodes.. Surgery, 195, 110204. https://doi.org/10.1016/j.surg.2026.110204
MLA
Walter R F Donica, et al.. "Evaluating the effect of postmastectomy radiotherapy and extent of axillary surgery in cancer patients with 1-2 positive lymph nodes.." Surgery, vol. 195, 2026, pp. 110204.
PMID
42001644 ↗
Abstract 한글 요약
[BACKGROUND] Radiation therapy prevents locoregional recurrence and improves outcomes in patients with positive lymph nodes undergoing mastectomy. Axillary lymph node dissection combined with radiation has not provided additional survival benefit. We evaluated the efficacy of postmastectomy radiation therapy and the effect of extent of axillary surgery.
[METHODS] Women with pT1-T2 breast cancer undergoing mastectomy with 1-2 positive lymph nodes were identified within the National Cancer Database from 2012 to 2021. Propensity-weighted Kaplan-Meier survival and Cox proportional hazards models were constructed to compare overall survival between groups.
[RESULTS] A total of 71,776 patients met inclusion criteria, with 39,319 (55%) receiving postmastectomy radiation therapy. Most patients had T1c (36%) or T2 (51%) disease and 1 positive lymph node (75%). A little over half (56%) underwent axillary lymph node dissection. Patients receiving postmastectomy radiation therapy were younger; had fewer comorbidities; and were more likely to have T2 disease, have 2 positive lymph nodes (33% vs 19%, P < .001), and undergo sentinel lymph node biopsy (49% vs 40%, P < .001). Ten-year OS probabilities were higher for patients receiving postmastectomy radiation therapy compared with patients who did not. Adding axillary lymph node dissection did not show an overall survival benefit. These differences persisted in a propensity-weighted Cox model adjusting for significant prognostic factors, where postmastectomy radiation therapy was associated with a 26% reduction in risk of death (hazard ratio 0.74 [95% confidence interval 0.70-0.78]), but the addition of axillary lymph node dissection was not (odds ratio 0.98 [0.92-1.03]) CONCLUSION: Data from the National Cancer Database support omission of further axillary surgery in patients with early-stage breast cancer with 1 to 2 positive lymph nodes undergoing postmastectomy radiation therapy and confirm the benefit of postmastectomy radiation therapy shown in most prospective studies.
[METHODS] Women with pT1-T2 breast cancer undergoing mastectomy with 1-2 positive lymph nodes were identified within the National Cancer Database from 2012 to 2021. Propensity-weighted Kaplan-Meier survival and Cox proportional hazards models were constructed to compare overall survival between groups.
[RESULTS] A total of 71,776 patients met inclusion criteria, with 39,319 (55%) receiving postmastectomy radiation therapy. Most patients had T1c (36%) or T2 (51%) disease and 1 positive lymph node (75%). A little over half (56%) underwent axillary lymph node dissection. Patients receiving postmastectomy radiation therapy were younger; had fewer comorbidities; and were more likely to have T2 disease, have 2 positive lymph nodes (33% vs 19%, P < .001), and undergo sentinel lymph node biopsy (49% vs 40%, P < .001). Ten-year OS probabilities were higher for patients receiving postmastectomy radiation therapy compared with patients who did not. Adding axillary lymph node dissection did not show an overall survival benefit. These differences persisted in a propensity-weighted Cox model adjusting for significant prognostic factors, where postmastectomy radiation therapy was associated with a 26% reduction in risk of death (hazard ratio 0.74 [95% confidence interval 0.70-0.78]), but the addition of axillary lymph node dissection was not (odds ratio 0.98 [0.92-1.03]) CONCLUSION: Data from the National Cancer Database support omission of further axillary surgery in patients with early-stage breast cancer with 1 to 2 positive lymph nodes undergoing postmastectomy radiation therapy and confirm the benefit of postmastectomy radiation therapy shown in most prospective studies.